Differentiating Between the Classes of Gastric Cancer

Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.